Author： Boland Patrick M. Ma Wen Wee
Publisher： MDPI
E-ISSN： 2072-6694|9|5|50-50
ISSN： 2072-6694
Source： Cancers, Vol.9, Iss.5, 2017-05, pp. : 50-50
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The recent success of anti-PD1 drugs in metastatic colorectal cancer patients with mismatch repair deficiency generated overwhelming enthusiasm for immunotherapy in the disease. However, patients with mismatch repair deficient colorectal cancer represent only a small subset of the metastatic population. Current research focuses on advancing immunotherapy to earlier stages of the disease including adjuvant and first-line metastatic settings, and on inducing sensitivity to immune checkpoint inhibitor therapy through a combinatorial approach. Here, we review the contemporary understanding of the immune and molecular landscape in colorectal cancer and discuss ongoing clinical trials evaluating novel combination regimens based on immune checkpoint inhibitors.
Related content
Access to resources
Recommend
By Yamamoto Nobuto Suyama Hirofumi Nakazato Hiroaki Yamamoto Nobuyuki Koga Yoshihiko
Cancer Immunology, Immunotherapy, Vol. 57, Iss. 7, 2008-07 ,pp. :